Triple Agonism Based Therapies for Obesity.

Area of Science:

• Pharmacology
• Endocrinology
• Metabolic Diseases

Background:

• Glucagon-like peptide 1 (GLP-1) receptor agonists (RA) have revolutionized obesity and type 2 diabetes (T2D) management.
• Tirzepatide, a dual GLP-1/glucose-dependent insulinotropic polypeptide (GIP) RA, represents a significant advancement in incretin-based therapies.
• Triple agonists targeting GLP-1, GIP, and glucagon receptors are emerging as a promising next generation of treatments.

Purpose of the Study:

• To review the rationale behind the development of triple incretin agonists.
• To summarize clinical trial data for retatrutide, a leading triple agonist candidate.
• To highlight the potential of retatrutide in managing obesity, T2D, and associated cardiometabolic risk factors.

Main Methods:

• Review of published clinical trial data, focusing on phase 2 studies of retatrutide.
• Analysis of retatrutide's efficacy in weight loss, glycemic control (HbA1c), and cardiometabolic parameters.
• Assessment of retatrutide's safety profile and common adverse events.

Main Results:

• Retatrutide demonstrated substantial mean weight loss: up to 24.2% in obesity and 16.9% in T2D.
• Significant HbA1c improvement (2.2%) in T2D, with 82% achieving HbA1c ≤ 6.5%.
• Marked improvements in blood pressure, lipids, waist circumference, and hepatic steatosis (82% reduction).

Conclusions:

• Retatrutide is the first triple agonist with published phase 2 data, showing potent effects on weight and metabolic health.
• Gastrointestinal symptoms were the most frequent side effects; no major safety concerns were identified.
• Phase 3 trials are underway to confirm efficacy, safety, and cardiovascular/renal outcomes, positioning retatrutide as a potential leading therapy for obesity and T2D.